Related Experiment Video
Updated: Aug 10, 2026

Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport
Published on: November 27, 2016
Bilary disposition of adriamycin
Adriamycin (doxorubicin) and its metabolites are excreted in bile, with some metabolites unique to bile. Impaired liver function may increase adriamycin toxicity due to reduced drug clearance.
Area of Science:
- Pharmacology
- Oncology
- Drug Metabolism
Background:
- Adriamycin (doxorubicin) is a key chemotherapy agent for various cancers.
- Understanding adriamycin's excretion pathways is crucial for managing toxicity.
- Biliary excretion of adriamycin and its metabolites has not been fully elucidated.
Purpose of the Study:
- To investigate the biliary excretion of adriamycin and its metabolites in a patient with abdominal histiocytic lymphoma.
- To characterize the pharmacokinetic profile of adriamycin and its metabolites in plasma, urine, and bile.
Main Methods:
- A patient with a T-tube and normal liver function received adriamycin for lymphoma.
- Plasma, urine, and bile samples were collected post-administration.
- Adriamycin and metabolites were extracted and analyzed using thin-layer chromatography.
Main Results:
- Adriamycin's plasma elimination half-life was 25.2 hours.
- Bile contained adriamycin and 11 metabolites, including 4 novel compounds.
- 41% of the adriamycin dose was excreted in bile within 7 days, with adriamycinol as the major metabolite.
- Hepatic and renal clearance favored adriamycin over adriamycinol.
Conclusions:
- Biliary excretion is a significant route for adriamycin and its metabolites.
- Novel metabolites were identified in bile, suggesting unique metabolic pathways.
- Liver function significantly impacts adriamycin clearance and potential toxicity.
More Related Videos
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
05:22Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma
Published on: February 13, 2026
Related Concept Videos
Drug Biotransformation: Overview
Drug Elimination: Non-Renal Routes
Hepatic Drug Excretion: Enterohepatic Cycling
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Hepatic Drug Excretion: Influencing Factors
Hepatic Drug Clearance: Role of Transporters
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase